Neoadjuvant treatment of unresectable BRAF-mutated ATCs with BRAF/MEK inhibitors is associated with significant, rapid therapeutic responses, rendering them surgically operable in many cases (Cabanillas et al. 2018, Wang et al. 2019, Maniakas et al. 2020). Here, BRAF is linked to Ehlers-Danlos syndrome, musculocontractural type.